Tricia Lin is a prominent inventor based in Spring House, PA, known for her significant contributions to the field of biotechnology. With a total of three patents to her name, she has made remarkable advancements in the development of engineered molecules that have therapeutic applications.

Latest Patents

Tricia Lin's latest patents focus on cysteine engineered fibronectin type III domain binding molecules. These innovations involve creating monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules that include one or more free cysteine amino acids. The process involves mutagenizing a nucleic acid sequence of a parent molecule and replacing specific amino acid residues with cysteine. This leads to the expression and recovery of the cysteine engineered FN3 domain containing molecules. These isolated molecules can be covalently attached to detection labels or drug moieties for therapeutic use.

Career Highlights

Tricia Lin is currently employed at Janssen Biotech, Inc., where she continues to push the boundaries of biotechnology. Her work has been instrumental in developing innovative solutions that address critical health challenges.

Collaborations

Tricia collaborates with notable colleagues, including Shalom Goldberg and Steven Jacobs, who contribute to her research and development efforts.

Conclusion

Tricia Lin's work exemplifies the spirit of innovation in biotechnology, showcasing her dedication to advancing therapeutic solutions through her patented inventions. Her contributions are paving the way for future breakthroughs in the field.

This text is generated by artificial intelligence and may not be accurate.